Hexarelin vs PT-141 (Bremelanotide)
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Hexarelin
Hexarelin is a potent synthetic hexapeptide growth hormone secretagogue. It provides the strongest GH release among GHRPs but is associated with rapid desensitization of receptors.
Full details →PT-141 (Bremelanotide)
PT-141, also known as Bremelanotide, is a synthetic peptide analog of alpha-melanocyte-stimulating hormone. It is the only FDA-approved treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women.
Full details →Side-by-Side Comparison
| Aspect | Hexarelin | PT-141 (Bremelanotide) |
|---|---|---|
| Dose Range | 100 mcg–300 mcg | 1.8 mg |
| Frequency | 2x daily | Less than daily |
| Cycle Length | 8–12 weeks | 4–12 weeks |
| Route | subcutaneous | subcutaneous |
| Mechanism | Acts as a ghrelin mimetic with high potency at the GHS receptor. Provides powerful GH release but receptor desensitization occurs faster than with other GHRPs, requiring cycling. | PT-141 activates melanocortin receptors (MC3R and MC4R) in the central nervous system, particularly in areas associated with sexual arousal. Unlike PDE5 inhibitors, it works through the nervous system rather than the vascular system. |
| Typical Dosage | Typical dosing: 100-200mcg administered 2-3 times daily for 4-6 weeks, followed by an equal off period to allow receptor resensitization. | FDA-approved dose: 1.75mg administered subcutaneously at least 45 minutes before anticipated sexual activity. Not to be used more than once within 24 hours or more than 8 times per month. |
| Administration | Subcutaneous injection. Cycling is essential to maintain effectiveness. Often used in short bursts rather than continuous protocols. | Subcutaneous injection in the abdomen. Available as Vyleesi (commercial product). Research use may involve different dosing protocols. |
| Side Effects | Water retention, cortisol and prolactin increase, hunger (moderate), tingling, and potential blood pressure effects. | Common side effects include nausea (40% of users), flushing, headache, and injection site reactions. Transient blood pressure increases may occur. |
| Best For |
What They Have in Common
Hexarelin, PT-141 (Bremelanotide) are both commonly used for:
Key Differences
Unique to Hexarelin:
Which Has Stronger Evidence?
- Recovery & Healing: Hexarelin has stronger research support.
| Goal | Hexarelin | PT-141 (Bremelanotide) |
|---|---|---|
| Recovery & Healing | medium | low |
Key Studies
Hexarelin
- Hexarelin promotes the survival of retinal ganglion cells after optic nerve transection.
Indian journal of pharmacology, 2026
- Hexarelin alleviates apoptosis on ischemic acute kidney injury via MDM2/p53 pathway.
European journal of medical research, 2023
- Hexarelin attenuates abdominal aortic aneurysm formation by inhibiting SMC phenotype switch and inflammasome activation.
Microvascular research, 2022
PT-141 (Bremelanotide)
- Small Effects, Questionable Outcomes: Bremelanotide for Hypoactive Sexual Desire Disorder.
Journal of sex research, 2024
- Safety Profile of Bremelanotide Across the Clinical Development Program.
Journal of women's health (2002), 2022
- Bremelanotide for Treatment of Female Hypoactive Sexual Desire.
Neurology international, 2022
Ready to Learn More?
Looking for trusted sources?